Current portfolio

Egle Therapeutics

Egle is developing a game changer in the field of immunomodulating T-regulatory cells (Tregs) through the unique concept of Treg starving

  • Sector
    Healthcare
  • Country
    France
  • Fund
    LSP 7
  • Entry
    2021
  • Web

Subscribe for the latest updates

Subscribe to EQT's press releases, regulatory press releases and updates.

Type of news
Preferred language
EQT logo
A purpose-driven global investment organization
© EQT AB 2022. EQT AB (PUBL). REGISTRATED OFFICE IN STOCKHOLM, SWEDEN. REGISTRATION NUMBER: 556849-4180